Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Kenvue

Kenvue Stock Outlook: Is Wall Street Bullish or Bearish?

Kenvue has outpaced the broader market over the past year, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Kenvue Stock Has Unusual Put Option Activity After Lower Q2 Sales and CEO Firing

Kenvue, which manufactures Band-Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO had left. Put options are showing unusually high volume today.

Barchart

Asian shares mostly decline as worries continue over Trump's tariffs

Asian shares are trading mostly lower as worries about President Donald Trump’s latest updates to his tariffs weighed on investor sentiments

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Tylenol-Maker Kenvue Launches Turnaround Plans. How Should You Play KVUE Stock Here?

Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to $27.

Barchart

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

The company will likely focus on off-loading smaller beauty brands.

Fortune

Kenvue Yo-Yoes After Tylenol-Maker Unveils New CEO, Strategic Review

Kenvue stock yo-yoes Monday after the company — known for brands like Tylenol — announced a new CEO and strategic review.

Investors Business Daily

How Earle Dickson Healed Wound Care With The Band-Aid

When Earle Dickson (1892-1961) invented the Band-Aid, treatments for minor cuts and scrapes were dicey.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Is Kenvue Stock Outperforming the Nasdaq?

Despite its recent underperformance, Kenvue has outpaced the Nasdaq over the past year, and analysts remain moderately bullish on the stock’s prospects.

Barchart

Kenvue Fights to Shield Brands Like Listerine and Tylenol Amid £112m Tariff Shock

Kenvue customers are expected to be prepared for price hikes as companies that sell directly to consumers grapple with rising costs.

International Business Times UK

Are Wall Street Analysts Predicting Kenvue Stock Will Climb or Sink?

Kenvue has outpaced the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

2 Under-the-Radar Consumer Staples Stocks With Big Dividends

Edgewell and Kenvue are under-the-radar consumer staples stocks poised to gain as the U.S. dollar declines. Learn why they may boost your income portfolio.

MarketBeat

Is Wall Street Bullish or Bearish on Kenvue Stock?

Despite Kenvue trailing the broader market over the past year, Wall Street analysts maintain a moderately bullish outlook on the stock's potential.

Barchart

How Is Kenvue’s Stock Performance Compared to Other Consumer Defensive Stocks

With Kenvue slightly lagging behind other consumer defensive stocks over the past year, Wall Street remains cautiously optimistic about its prospects.

Barchart

Johnson & Johnson Risks UK Lawsuit Over Talc Cancer Claim

UK claimants announced Wednesday legal action against US pharmaceutical and cosmetics giant Johnson & Johnson, alleging that women diagnosed with cancers were exposed to asbestos in the company's talcum powder.

International Business Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stocks With Rising Relative Strength: Kenvue

Kenvue shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Kenvue Shows Rising Price Performance With Jump To 82 RS Rating

Kenvue shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Investors Business Daily

Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises

Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best pipeline" ever.

Investors Business Daily

Nvidia Among Five Best S&P 500 Stocks Today

Pfizer spinoff Kenvue led the S&P 500 on Monday. Nvidia stock was close behind, breaking out to a record high.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

What’s Behind the Rally in Kenvue Stock Today?

Starboard Value is reportedly eyeing changes at KVUE as the stock underperforms the broader market.

Investors Business Daily

Starboard Value Buys Into Dow Jones Spinoff; ELF Beauty Rallies

Elf Beauty appeared to rally along with KVUE on Monday.

Barchart

Kenvue Stock: Is KVUE Outperforming the Consumer Defensive Sector?

Kenvue has recently outperformed the consumer defensive sector, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

3 Defensive Dividend Stocks to Protect Against Pre-Election Volatility

As the U.S. presidential election nears, here are three defensive dividend-paying stocks to help shield your portfolio from pre-election volatility.

Barchart

This Dividend Aristocrat Just Had Its Best Day Ever After Earnings

This dividend aristocrat crushed Q2 earnings and issued strong guidance, and still has some fuel left in the tank for more growth.

Barchart

3 Dividend Stocks Set to Triple Your Income in the Next Decade

Looking for a lifetime of increasing dividends? Here's 3 stocks that could fit the bill.

The Independent UK

This Morning’s Dr Zoe Williams: Nobody should be smoking at home where there’s a child or pregnant mother

Quitting smoking can be extremely difficult, but there are lots of treatments options out there to help.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.